Daniel was born and received his education in Taiwan. His scientific focus areas are in DNA repair, cancer biology, molecular biology, biochemistry, drug discovery, and drug combination. He received his B.S. from National Dong Hwa University in 2004. Daniel obtained M.S. from National Chung Hsing University in 2006. Through the use of forward genetics, he studied gene functions that affect flowering and fertilizing in rice. Afterward, Daniel devoted himself in cancer research at Academia Sinica and National Yang-Ming University where he received his Ph.D. in 2014. His Ph.D. project was to evaluate therapeutic effects, preclinical toxicity, and the mode of action of novel DNA alkylating agents for treating cancer. Then he moved to George Washington University for postdoc training from 2016 to 2018. He investigated mechanisms involved in cisplatin or gemcitabine resistant cancer. Meanwhile, he also studied the killing cancer effects and mechanisms of novel ribonucleotide reductase (RNR) inhibitor. In August 2018 Daniel began his adventure at Penn State College of Medicine. He is currently studying metabolic changes induced by ATM inhibitors in ovarian cancer.